Loading
Palacaparib is an experimental small-molecule drug from AstraZeneca in phase 2 trials for ovarian cancer, non-small-cell lung cancer and endometrial cancer, aimed at PARP.
Palacaparib (AZD9574) is a small-molecule drug developed by AstraZeneca. Its target is PARP (the sponsor names PARP). The sponsor states: An oral PARP inhibitor that blocks PARP enzyme activity, preventing DNA repair in cancer cells, particularly tumours with homologous recombination deficiency. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in ovarian cancer, non-small-cell lung cancer and endometrial cancer. The largest, NCT05797168, plans to enrol 602 participants with primary completion expected 2028-08-04. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
An oral PARP inhibitor that blocks PARP enzyme activity, preventing DNA repair in cancer cells, particularly tumours with homologous recombination deficiency. Connects to PARP.
1.Palacaparib slips into a pocket on PARP.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Palacaparib" OR ABSTRACT:"Palacaparib" OR TITLE:"AZD9574" OR ABSTRACT:"AZD9574") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Palacaparib, not a curated reading list.
Shares Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors, A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies, PARP, Endometrial cancer and the tag pipeline.
Shares Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors, AstraZeneca, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer, AstraZeneca and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.